報價延遲最少15分鐘:2026/04/21 19:27 EDT
盤後時段
|
||||
|
0.381 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.3774
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.75/-0.11
|
|
企業價值
300.54M
|
| 資產負債 |
|
每股賬面淨值
-0.52
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
48.47M
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension). |
